share_log

Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial

Benzinga Real-time News ·  Sep 22, 2022 07:24
  • Nanobiotix (NASDAQ:NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy.
  • The combo includes NBTXR3 plus Merck & Co Inc's (NYSE:MRK) Keytruda pembrolizumab or Bristol Myers Squibb Co's (NYSE:BMY) Opdivo (nivolumab).
  • The combined dose escalation and dose expansion parts of Study 1100 are expected to enroll up to 141 patients.
  • Related: Nanobiotix's Radiotherapy Combo Therapy Shows Boosted Anti-Tumor Activity In Preclinical Studies.
  • The complete dose escalation part enrolled 29 patients in three cohorts. Based on the study's results, the RP2D for all three cohorts was determined to be 33% of gross tumor volume.
  • Nanobiotix has amended the ongoing expansion phase of Study 1100. The amended dose expansion part also has three cohorts. However, the cohorts have been re-designed further to explore NBTXR3 plus anti-PD-1 in several immunotherapy-eligible indications, focusing on patients that are either naïve or resistant to prior immunotherapy.
  • The company expects to provide updated clinical data from Study 1100 in Q4 2022. The registrational phase 3 protocol submission is expected in Q1 2023, followed by modification of the study design.
  • Price Action: NBTX shares closed at $4.04 on Wednesday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment